Change From Baseline in Overall Scores (Global Health Status) and Individual Scales of the EORTC QLQ-C30 at Week 48 and Week 96
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP · Source last updated 2026-08-28
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Baseline, week 48 and week 96
What was measured
The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) assesses the quality of life of cancer patients. It consists of functioning scales, symptom scales, and the global health status quality of life (QoL) scale.
A high score for functional and QoL items/scales from the QLQ-30 represents better function and QOL. A high score in symptoms items from QLQ-30 represents worse symptoms.
Analysis population: Full Analysis Set: All participants who had an EORTC QLQ-C30 assessment both at baseline and at week 48.
Groups in this outcome
Asciminib (All Asciminib )
Patients took asciminib 80 mg QD under fasting conditions on ongoing basis.
Investigator Selected TKI (All Comparators)
Patients will take on ongoing basis the Investigator selected TKIs (imatinib, nilotinib, dasatinib or bosutinib)
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Asciminib (All Asciminib )
79
Investigator Selected TKI (All Comparators)
70
Reported measurements
Global health status/QoL
Very much better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
10
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
6
Not reported
Not reported
Not reported
Not reported
Moderately better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
18
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
7
Not reported
Not reported
Not reported
Not reported
A little better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
6
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
6
Not reported
Not reported
Not reported
Not reported
Unchanged
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
28
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
26
Not reported
Not reported
Not reported
Not reported
A little worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
5
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
6
Not reported
Not reported
Not reported
Not reported
Moderately worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
10
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
12
Not reported
Not reported
Not reported
Not reported
Very much worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
2
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
7
Not reported
Not reported
Not reported
Not reported
Physical functioning
Very much better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
3
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
3
Not reported
Not reported
Not reported
Not reported
Moderately better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
10
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
12
Not reported
Not reported
Not reported
Not reported
A little better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
16
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
12
Not reported
Not reported
Not reported
Not reported
Unchanged
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
32
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
26
Not reported
Not reported
Not reported
Not reported
A little worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
7
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
8
Not reported
Not reported
Not reported
Not reported
Moderately worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
10
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
6
Not reported
Not reported
Not reported
Not reported
Very much worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
1
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
3
Not reported
Not reported
Not reported
Not reported
Role functioning
Very much better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
5
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
7
Not reported
Not reported
Not reported
Not reported
Moderately better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
10
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
7
Not reported
Not reported
Not reported
Not reported
A little better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Unchanged
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
54
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
41
Not reported
Not reported
Not reported
Not reported
A little worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Moderately worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
4
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
7
Not reported
Not reported
Not reported
Not reported
Very much worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
6
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
8
Not reported
Not reported
Not reported
Not reported
Emotional functioning
Very much better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
9
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
10
Not reported
Not reported
Not reported
Not reported
Moderately better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
7
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
6
Not reported
Not reported
Not reported
Not reported
A little better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
14
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
9
Not reported
Not reported
Not reported
Not reported
Unchanged
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
31
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
24
Not reported
Not reported
Not reported
Not reported
A little worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
7
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
10
Not reported
Not reported
Not reported
Not reported
Moderately worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
5
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
5
Not reported
Not reported
Not reported
Not reported
Very much worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
6
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
6
Not reported
Not reported
Not reported
Not reported
Cognitive functioning
Very much better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
3
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
1
Not reported
Not reported
Not reported
Not reported
Moderately better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
13
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
8
Not reported
Not reported
Not reported
Not reported
A little better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Unchanged
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
44
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
36
Not reported
Not reported
Not reported
Not reported
A little worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Moderately worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
16
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
19
Not reported
Not reported
Not reported
Not reported
Very much worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
3
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
6
Not reported
Not reported
Not reported
Not reported
Social functioning
Very much better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
7
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
6
Not reported
Not reported
Not reported
Not reported
Moderately better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
14
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
6
Not reported
Not reported
Not reported
Not reported
A little better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Unchanged
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
51
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
40
Not reported
Not reported
Not reported
Not reported
A little worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Moderately worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
4
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
7
Not reported
Not reported
Not reported
Not reported
Very much worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
3
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
11
Not reported
Not reported
Not reported
Not reported
Fatigue
Very much better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
19
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
11
Not reported
Not reported
Not reported
Not reported
Moderately better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
16
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
16
Not reported
Not reported
Not reported
Not reported
A little better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Unchanged
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
26
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
16
Not reported
Not reported
Not reported
Not reported
A little worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Moderately worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
11
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
11
Not reported
Not reported
Not reported
Not reported
Very much worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
7
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
16
Not reported
Not reported
Not reported
Not reported
Nausea and vomiting
Very much better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
1
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
1
Not reported
Not reported
Not reported
Not reported
Moderately better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
7
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
5
Not reported
Not reported
Not reported
Not reported
A little better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Unchanged
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
67
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
48
Not reported
Not reported
Not reported
Not reported
A little worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Moderately worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
3
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
11
Not reported
Not reported
Not reported
Not reported
Very much worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
1
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
5
Not reported
Not reported
Not reported
Not reported
Pain
Very much better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
9
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
3
Not reported
Not reported
Not reported
Not reported
Moderately better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
17
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
11
Not reported
Not reported
Not reported
Not reported
A little better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Unchanged
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
45
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
37
Not reported
Not reported
Not reported
Not reported
A little worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Moderately worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
5
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
10
Not reported
Not reported
Not reported
Not reported
Very much worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
3
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
9
Not reported
Not reported
Not reported
Not reported
Dyspnoea
Very much better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
11
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
9
Not reported
Not reported
Not reported
Not reported
Moderately better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
A little better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Unchanged
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
59
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
49
Not reported
Not reported
Not reported
Not reported
A little worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Moderately worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Very much worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
9
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
12
Not reported
Not reported
Not reported
Not reported
Insomnia
Very much better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
14
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
10
Not reported
Not reported
Not reported
Not reported
Moderately better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
A little better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Unchanged
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
50
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
43
Not reported
Not reported
Not reported
Not reported
A little worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Moderately worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Very much worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
15
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
17
Not reported
Not reported
Not reported
Not reported
Appetite loss
Very much better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
16
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
11
Not reported
Not reported
Not reported
Not reported
Moderately better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
A little better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Unchanged
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
59
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
51
Not reported
Not reported
Not reported
Not reported
A little worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Moderately worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Very much worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
4
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
8
Not reported
Not reported
Not reported
Not reported
Constipation
Very much better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
8
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
14
Not reported
Not reported
Not reported
Not reported
Moderately better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
A little better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Unchanged
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
58
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
40
Not reported
Not reported
Not reported
Not reported
A little worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Moderately worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Very much worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
13
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
16
Not reported
Not reported
Not reported
Not reported
Diarrhoea
Very much better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
11
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
8
Not reported
Not reported
Not reported
Not reported
Moderately better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
A little better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Unchanged
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
61
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
43
Not reported
Not reported
Not reported
Not reported
A little worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Moderately worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Very much worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
7
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
19
Not reported
Not reported
Not reported
Not reported
Financial difficulties
Very much better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
12
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
14
Not reported
Not reported
Not reported
Not reported
Moderately better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
A little better
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Unchanged
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
63
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
49
Not reported
Not reported
Not reported
Not reported
A little worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Moderately worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
0
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
0
Not reported
Not reported
Not reported
Not reported
Very much worse
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Asciminib (All Asciminib )
4
Not reported
Not reported
Not reported
Not reported
Investigator Selected TKI (All Comparators)
7
Not reported
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
value
10
group Id
OG001
value
6
title
Very much better
measurements
group Id
OG000
value
18
group Id
OG001
value
7
title
Moderately better
measurements
group Id
OG000
value
6
group Id
OG001
value
6
title
A little better
measurements
group Id
OG000
value
28
group Id
OG001
value
26
title
Unchanged
measurements
group Id
OG000
value
5
group Id
OG001
value
6
title
A little worse
measurements
group Id
OG000
value
10
group Id
OG001
value
12
title
Moderately worse
measurements
group Id
OG000
value
2
group Id
OG001
value
7
title
Very much worse
title
Global health status/QoL
categories
measurements
group Id
OG000
value
3
group Id
OG001
value
3
title
Very much better
measurements
group Id
OG000
value
10
group Id
OG001
value
12
title
Moderately better
measurements
group Id
OG000
value
16
group Id
OG001
value
12
title
A little better
measurements
group Id
OG000
value
32
group Id
OG001
value
26
title
Unchanged
measurements
group Id
OG000
value
7
group Id
OG001
value
8
title
A little worse
measurements
group Id
OG000
value
10
group Id
OG001
value
6
title
Moderately worse
measurements
group Id
OG000
value
1
group Id
OG001
value
3
title
Very much worse
title
Physical functioning
categories
measurements
group Id
OG000
value
5
group Id
OG001
value
7
title
Very much better
measurements
group Id
OG000
value
10
group Id
OG001
value
7
title
Moderately better
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
A little better
measurements
group Id
OG000
value
54
group Id
OG001
value
41
title
Unchanged
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
A little worse
measurements
group Id
OG000
value
4
group Id
OG001
value
7
title
Moderately worse
measurements
group Id
OG000
value
6
group Id
OG001
value
8
title
Very much worse
title
Role functioning
categories
measurements
group Id
OG000
value
9
group Id
OG001
value
10
title
Very much better
measurements
group Id
OG000
value
7
group Id
OG001
value
6
title
Moderately better
measurements
group Id
OG000
value
14
group Id
OG001
value
9
title
A little better
measurements
group Id
OG000
value
31
group Id
OG001
value
24
title
Unchanged
measurements
group Id
OG000
value
7
group Id
OG001
value
10
title
A little worse
measurements
group Id
OG000
value
5
group Id
OG001
value
5
title
Moderately worse
measurements
group Id
OG000
value
6
group Id
OG001
value
6
title
Very much worse
title
Emotional functioning
categories
measurements
group Id
OG000
value
3
group Id
OG001
value
1
title
Very much better
measurements
group Id
OG000
value
13
group Id
OG001
value
8
title
Moderately better
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
A little better
measurements
group Id
OG000
value
44
group Id
OG001
value
36
title
Unchanged
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
A little worse
measurements
group Id
OG000
value
16
group Id
OG001
value
19
title
Moderately worse
measurements
group Id
OG000
value
3
group Id
OG001
value
6
title
Very much worse
title
Cognitive functioning
categories
measurements
group Id
OG000
value
7
group Id
OG001
value
6
title
Very much better
measurements
group Id
OG000
value
14
group Id
OG001
value
6
title
Moderately better
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
A little better
measurements
group Id
OG000
value
51
group Id
OG001
value
40
title
Unchanged
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
A little worse
measurements
group Id
OG000
value
4
group Id
OG001
value
7
title
Moderately worse
measurements
group Id
OG000
value
3
group Id
OG001
value
11
title
Very much worse
title
Social functioning
categories
measurements
group Id
OG000
value
19
group Id
OG001
value
11
title
Very much better
measurements
group Id
OG000
value
16
group Id
OG001
value
16
title
Moderately better
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
A little better
measurements
group Id
OG000
value
26
group Id
OG001
value
16
title
Unchanged
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
A little worse
measurements
group Id
OG000
value
11
group Id
OG001
value
11
title
Moderately worse
measurements
group Id
OG000
value
7
group Id
OG001
value
16
title
Very much worse
title
Fatigue
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
1
title
Very much better
measurements
group Id
OG000
value
7
group Id
OG001
value
5
title
Moderately better
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
A little better
measurements
group Id
OG000
value
67
group Id
OG001
value
48
title
Unchanged
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
A little worse
measurements
group Id
OG000
value
3
group Id
OG001
value
11
title
Moderately worse
measurements
group Id
OG000
value
1
group Id
OG001
value
5
title
Very much worse
title
Nausea and vomiting
categories
measurements
group Id
OG000
value
9
group Id
OG001
value
3
title
Very much better
measurements
group Id
OG000
value
17
group Id
OG001
value
11
title
Moderately better
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
A little better
measurements
group Id
OG000
value
45
group Id
OG001
value
37
title
Unchanged
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
A little worse
measurements
group Id
OG000
value
5
group Id
OG001
value
10
title
Moderately worse
measurements
group Id
OG000
value
3
group Id
OG001
value
9
title
Very much worse
title
Pain
categories
measurements
group Id
OG000
value
11
group Id
OG001
value
9
title
Very much better
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
Moderately better
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
A little better
measurements
group Id
OG000
value
59
group Id
OG001
value
49
title
Unchanged
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
A little worse
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
Moderately worse
measurements
group Id
OG000
value
9
group Id
OG001
value
12
title
Very much worse
title
Dyspnoea
categories
measurements
group Id
OG000
value
14
group Id
OG001
value
10
title
Very much better
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
Moderately better
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
A little better
measurements
group Id
OG000
value
50
group Id
OG001
value
43
title
Unchanged
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
A little worse
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
Moderately worse
measurements
group Id
OG000
value
15
group Id
OG001
value
17
title
Very much worse
title
Insomnia
categories
measurements
group Id
OG000
value
16
group Id
OG001
value
11
title
Very much better
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
Moderately better
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
A little better
measurements
group Id
OG000
value
59
group Id
OG001
value
51
title
Unchanged
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
A little worse
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
Moderately worse
measurements
group Id
OG000
value
4
group Id
OG001
value
8
title
Very much worse
title
Appetite loss
denoms
counts
group Id
OG000
value
79
group Id
OG001
value
70
units
Participants
description
The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) assesses the quality of life of cancer patients. It consists of functioning scales, symptom scales, and the global health status quality of life (QoL) scale.
A high score for functional and QoL items/scales from the QLQ-30 represents better function and QOL. A high score in symptoms items from QLQ-30 represents worse symptoms.
groups
description
Patients took asciminib 80 mg QD under fasting conditions on ongoing basis.
id
OG000
title
Asciminib (All Asciminib )
description
Patients will take on ongoing basis the Investigator selected TKIs (imatinib, nilotinib, dasatinib or bosutinib)
id
OG001
title
Investigator Selected TKI (All Comparators)
param Type
COUNT_OF_PARTICIPANTS
population Description
Full Analysis Set: All participants who had an EORTC QLQ-C30 assessment both at baseline and at week 48.
reporting Status
POSTED
time Frame
Baseline, week 48 and week 96
title
Change From Baseline in Overall Scores (Global Health Status) and Individual Scales of the EORTC QLQ-C30 at Week 48 and Week 96
Triangle